drugset / Trial / NCT06226363
Phase I Study of LNF1901 in Advanced Malignant Tumors
Phase 1
Not yet recruiting
82 enrolled
Shandong New Time Pharmaceutical Co., LTD
Sun Yat-sen University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2025-02-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LNF1901 | Monoclonal antibody | 0.003 mg/kg | — |
| Subject | LNF1901 | Monoclonal antibody | 0.03 mg/kg | — |
| Subject | LNF1901 | Monoclonal antibody | 0.1 mg/kg | — |
| Subject | LNF1901 | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | LNF1901 | Monoclonal antibody | 1 mg/kg | — |
| Subject | LNF1901 | Monoclonal antibody | 2 mg/kg | — |
| Subject | LNF1901 | Monoclonal antibody | 3 mg/kg | — |